Trimetrexate (isethionate)

Trimetrexate (CI-898) isethionate is an antibiotic, also a potent and orally active dihydrofolate reductase (DHFR) inhibitor, reducing the production of DNA and RNA precursors and leading to cell death, with IC50 values of 4.74 nM and 1.35 nM for human DHFR and Toxoplasma gondii DHFR. Trimetrexate isethionate can also inhibit the growth of various cancer cells. Trimetrexate isethionate can be used for researching Pneumocystis carinii pneumonia (PCP) and cancer[1][2][3][4][5].

Product Specifications

CAS Number

[82935-04-4]

Product Name Alternative

CI-898 (isethionate)

UNSPSC

12352005

Target

Antibiotic; Antifolate; Bacterial; Dihydrofolate reductase (DHFR) ; DNA/RNA Synthesis; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/trimetrexate-isethionate.html

Solubility

10 mM in DMSO

Smiles

OCCS(=O)(O)=O.NC1=NC(N)=C2C(C)=C(CNC3=CC(OC)=C(OC)C(OC)=C3)C=CC2=N1

Molecular Formula

C21H29N5O7S

Molecular Weight

495.55

References & Citations

[1]Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019 Feb 14;62 (3) :1562-1576.|[2]Fulton, B., et al. Trimetrexate. Drugs 49, 563–576 (1995) .|[3]Allegra CJ, et al. Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate. J Clin Invest. 1987 Feb;79 (2) :478-82.|[4]Dethloff LA, et al. Chronic toxicity of the anticancer agent trimetrexate in rats. Fundam Appl Toxicol. 1992 Jul;19 (1) :6-14.|[5]Grem JL, Voeller DM, Geoffroy F, Horak E, Johnston PG, Allegra CJ. Determinants of trimetrexate lethality in human colon cancer cells. Br J Cancer. 1994 Dec;70 (6) :1075-84.